New rapid testing method for Covid-19

Image source: Osaka University

News • Using AI nanopores

New rapid testing method for Covid-19

A rapid, accurate way of testing for Covid-19 infection would be a big step in overcoming the virus’ hold over our society.

Now, in an article published in Lab on a Chip, researchers from Osaka University have developed a promising solution: a novel platform that couples nanopore technology with artificial intelligence. 

What is a nanopore? A nanopore is a miniscule hole in a thin substrate, often a silicon wafer. A nanopore might range from several nanometers to several hundred nanometers in diameter — a scale small enough to work with Sars-CoV-2, the virus that causes Covid-19. Kaoru Murakami, the study’s lead author, explains: “Our technology involves looking at changes in the electrical current as different materials are passed through tiny nanopores. With the use of artificial intelligence, we can understand the structure, volume, and surface charge of different materials, including viruses.”

A major advantage of our nanopore system is that it is much less expensive [than RT-PCR] and has the potential to measure a larger number of samples in a given period of time

Masaaki Murakami

Sars-CoV-2 is typical of many other RNA viruses in that it constantly mutates, thereby changing the properties of the virus – including infection rates and symptoms. One infamous mutation of the virus, the Omicron variant, was first identified in November 2021 and is known for its ability to spread quickly. One of the greatest challenges for Covid-19 testing so far has been accurately determining the presence or absence of newly mutated variants in a sample. Thus, the researchers first sought to demonstrate that their platform could detect differences between six different variants of Sars-CoV-2. Next, they investigated whether their platform could identify Sars-CoV-2 strains in 241 saliva samples, collected from 132 people infected with Sars-CoV-2 and 109 uninfected people. Not only was the platform able to distinguish between Sars-CoV-2 variants, but it was also able to determine the presence of the Omicron variant 100% of the time. 

The researchers hypothesize that their AI-driven platform is detecting differences in the so-called spike proteins (also called S-proteins) that coat the surface of coronaviruses. These proteins, which tend to mutate very quickly, bind to host cell receptors and play a crucial role in penetrating host cells. 

Until now, the gold standard for Sars-CoV-2 detection has been a method called RT-PCR (the reverse transcription-polymerase chain reaction test). “Like RT-PCR, our AI-nanopore platform can detect coronavirus with high sensitivity and specificity. However, a major advantage of our nanopore system is that it is much less expensive and has the potential to measure a larger number of samples in a given period of time,” explains Masaaki Murakami, senior author. 

The benefits of this system are not specific to Sars-CoV-2; other RNA viruses also tend to have high mutation rates, and so this platform could be used to detect viruses such as influenza. The new platform could even be rapidly adapted to test for the next newly emerged infectious disease. 


Source: Osaka University

29.10.2023

Related articles

Photo

News • Preparing for the next pandemic

New rapid electronic diagnostic test for infectious diseases

A new molecular test for bacteria and viruses, including Sars-CoV-2, has been developed at the University of Surrey, as they warn that the world needs to be prepared for the next pandemic.

Photo

News • Deep mutational scanning for SARS-CoV-2

Preparing rapid tests for future coronavirus variants

How can rapid antigen tests be adjusted to reliably detect future variants of SARS-CoV-2? A research team funded by the National Institutes of Health is currently working on finding an answer.

Photo

News • Inhibition of Sars-CoV-2 proliferation

New 'hairpin' tool stops coronavirus in its tracks

A new way to inhibit the proliferation of Sars-CoV-2 opens up new perspectives in the fight against this coronavirus and other viral diseases that still have no medical treatment.

Related products

Subscribe to Newsletter